Bone Biologics Corporation (BBLG)
Market Cap | 1.34M |
Revenue (ttm) | n/a |
Net Income (ttm) | -6.10M |
Shares Out | 1.10M |
EPS (ttm) | -16.34 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 22,633 |
Open | 1.210 |
Previous Close | 1.210 |
Day's Range | 1.200 - 1.240 |
52-Week Range | 1.130 - 14.160 |
Beta | 0.72 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 12, 2024 |
About BBLG
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, ort... [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/7/b/press17-2487812.jpg)
First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that...
![](https://cdn.snapi.dev/images/v1/x/e/press15-2311880.jpg)
Bone Biologics Announces Closing of $2.0 Million Public Offering
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
![](https://cdn.snapi.dev/images/v1/s/j/press17-2306422.jpg)
Bone Biologics Announces Pricing of $2.0 Million Public Offering
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
![](https://cdn.snapi.dev/images/v1/d/w/press13-2303426.jpg)
Bone Biologics Reports Progress With NB1 Clinical Program
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1...
![](https://cdn.snapi.dev/images/v1/3/e/press12-2225552.jpg)
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
![](https://cdn.snapi.dev/images/v1/c/f/press20-2223878.jpg)
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
![](https://cdn.snapi.dev/images/v1/o/0/press1-2199889.jpg)
Bone Biologics Announces 1-for-8 Reverse Stock Split
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
![](https://cdn.snapi.dev/images/v1/u/7/press9-2165715.jpg)
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced r...
![](https://cdn.snapi.dev/images/v1/i/z/press4-2162487.jpg)
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agr...
![](https://cdn.snapi.dev/images/v1/f/a/press4-2077808.jpg)
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiative...
![](https://cdn.snapi.dev/images/v1/s/j/image34-1942073.jpeg)
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/h/y/medical1-1935716.jpg)
Bone Biologics stock plummets more than 50% after stock offering prices at deep discount
Shares of Bone Biologics Corp. BBLG plummeted 51.9% toward a record low in premarket trading Thursday, after the developer of regenerative medicine for bones announced the pricing of its relatively la...
![](https://cdn.snapi.dev/images/v1/f/q/press7-1934897.jpg)
Bone Biologics Prices $5.0 Million Underwritten Public Offering
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the p...
![](https://cdn.snapi.dev/images/v1/s/r/press12-1923367.jpg)
Bone Biologics Effects 1-for-30 Reverse Stock Split
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that a 1-for-30 reverse stock split became effe...
![](https://cdn.snapi.dev/images/v1/c/4/press19-1832208.jpg)
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committee (HREC)...
![](https://cdn.snapi.dev/images/v1/a/z/press18-1724444.jpg)
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract researc...
![](https://cdn.snapi.dev/images/v1/n/p/press3-1581276.jpg)
WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public Offering
JERSEY CITY, N.J. , Oct. 13, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services announced yesterday the closing of Bone Biologics ...
![](https://cdn.snapi.dev/images/v1/w/8/press9-1580197.jpg)
Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering
BURLINGTON, Mass.
![](https://cdn.snapi.dev/images/v1/p/x/press9-1573916.jpg)
CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering
BURLINGTON, Mass.--(BUSINESS WIRE)--Reissuing release to remove "million" after "$5,100,000" in the headline and first sentence of the text. The updated release reads: BONE BIOLOGICS PRICES $5,100,000...
![](https://cdn.snapi.dev/images/v1/s/a/press17-1573858.jpg)
WallachBeth Capital Announces Pricing of Bone Biologics $5,100,000 Underwritten Public Offering
JERSEY CITY, N.J. , Oct. 7, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Bone Biologics Corporation (N...
![](https://cdn.snapi.dev/images/v1/r/n/press1-1573601.jpg)
Bone Biologics Prices $5,100,000 Million Underwritten Public Offering
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces the pricing of an underwritten public offering ...
![](https://cdn.snapi.dev/images/v1/d/b/press2-1289627.jpg)
Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company's presi...
![](https://cdn.snapi.dev/images/v1/s/s/press15-1265365.jpg)
Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has entered into a supply agreement with MTF...
![](https://cdn.snapi.dev/images/v1/r/r/medical17-1178861.jpg)
Why Are Bone Biologics Shares Surging On Monday?
Newly listed Bone Biologics Corporation (NASDAQ: BBLG) shares are surging after the Company announced to present at the H.C. Wainwright BioConnect Virtual Conference.